A Multicenter, Randomized, Controlled, Open-Label, Group-Sequential, Phase 3 Study to Investigate the Efficacy, Safety, and Tolerability of Intravenous Gammagard Liquid (Immune Globulin Infusion, 10%) for Primary Infection Prophylaxis Compared With Secondary Infection Prophylaxis in Adult Subjects With Multiple Myeloma Receiving B-Cell Maturation Antigen×CD3-Directed Bispecific Antibody Therapy

Trial information

Medical condition

MM

Trial phase

Phase 3

Sponsor

Takeda

Start date

13/07/2026

Main objective

To compare primary versus secondary infection prophylaxis with intravenous Gammagard Liquid (IGI, 10%) in multiple myeloma patients receiving BCMA×CD3 bispecific antibody therapy, with time to first serious infection as the primary endpoint.

Locations and Contact points